Alkermes PLC said it is selling its Georgia manufacturing facility and global rights to its experimental pain treatment to Recro Pharma Inc., as the Irish specialty-pharmaceutical company seeks to focus on its pipeline of central-nervous-system treatments. Alkermes said it will receive a $50 million initial payment and up to $120 million in milestone payments.

READ FULL ARTICLE Curated publisher From The Wall Street Journal